Compare Five Below Inc (FIVE) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

Five Below (FIVE) trades at $213.35, down 0.11% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $1.68 beating expectations of $1.40, and raised its fiscal 2026 outlook. Revenue growth remains robust at $3.88 billion for 2025, with net income of $253.61 million. Analyst consensus is strongly bullish with a $298.44 price target, representing 40% upside potential from current levels.

FIVE presents a compelling growth story with strong fundamentals and positive analyst sentiment, though execution risks remain. The stock's premium valuation (P/E 19.14) requires continued strong performance to justify. Near-term catalysts include Q3 2026 earnings and the company's $600 million buyback program, while risks include consumer spending sensitivity and competitive pressures in the value retail space.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.